PMA device
Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire System
Senseonics, Incorporated · Continuous Glucose Monitor, Implanted, Adjunctive Use (QCD, Class III) · First FDA decision Dec 5, 2023, newest Dec 5, 2023Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "Eversense E3"
MAUDE reports
98
Brand "Eversense E3", since 2015
PubMed studies
0
Mentioning "Eversense E3"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire System, Eversense E3 Sensor, Eversense E3 InsertPMA supplement
P160048-S026 · Decided Dec 5, 2023 · 116 days after receipt · Normal 180 Day Track No User Fee
Device type: Continuous glucose monitor, implanted, adjunctive use (QCD) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38662CGS Administrators, LLCUpdated Sep 29, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38623Wellpoint FederalUpdated Jul 14, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38686WPS Insurance CorporationUpdated Jun 18, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38657Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38743Palmetto GBAUpdated Jul 19, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38664First Coast Service Options, Inc.Updated Jun 21, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38617Novitas Solutions, Inc.Updated Jun 21, 2024
- Home Blood Glucose MonitorsNational analysisReview closedCAG-00161NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Eversense E3", any status and sponsor, newest update first.
No registered device study names "Eversense E3".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Eversense E3", and for the whole product code for context.
This brand
98 reports: 44 malfunction, 54 injury, 0 death
Whole product code QCD
1,514 reports: 566 malfunction, 948 injury, 0 death
Newest reports for this brand
- EVERSENSE E3 SENSORInjury
3009862700-2026-00526 · Received Mar 9, 2026 · Event dated Oct 31, 2025
Device type: Sensor, Glucose, Implanted, Non-Adjunctive Use (QHJ)
Device problem as coded: Difficult to Remove
Patient problem as coded: Implant Pain
- EVERSENSE E3 SENSORInjury
3009862700-2026-00494 · Received Mar 8, 2026 · Event dated Feb 6, 2026
Device type: Sensor, Glucose, Implanted, Non-Adjunctive Use (QHJ)
Device problem as coded: Difficult to Remove
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- EVERSENSE E3 SENSORInjury
3009862700-2026-00492 · Received Mar 8, 2026 · Event dated Dec 29, 2025
Device type: Sensor, Glucose, Implanted, Non-Adjunctive Use (QHJ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Thrombosis/Thrombus
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0251-2020 · Started Sep 18, 2019
Reason given: Eversense Sensors have prematurely stopped functioning due to inadequate hydration of the sensor s glucose-sensing surface
Cause as FDA categorized it: Process control · Device type: Sensor, Glucose, Implanted, Non-Adjunctive Use (QHJ)
Published research
The most relevant PubMed records for "Eversense E3"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QCD.
- Eversense® Continuous Glucose Monitoring SystemSenseonics, Incorporated · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.